IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: Sweden
ID NLM: 8709065
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
21
12
2023
accepted:
16
03
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile. IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment. Comprehensive next-generation sequencing, TruSight Oncology 500, is used for screening. Patients with tumours harbouring molecular alterations with matched targeted therapies available in IMPRESS-Norway, are offered treatment. Currently, 24 drugs are available in the study. Primary study endpoints are percentage of patients offered treatment in the trial, and disease control rate (DCR) defined as complete or partial response or stable disease in evaluable patients at 16 weeks (W16) of treatment. Secondary endpoint presented is DCR in all treated patients. Between April 2021 and October 2023, 1,167 patients were screened, and an actionable mutation with matching drug was identified for 358 patients. By the data cut off 186 patients have initiated treatment, 170 had a minimum follow-up time of 16 weeks, and 145 also had evaluable disease. In patients with evaluable disease, the DCR was 40% (58/145). Secondary endpoint analysis of DCR in all treated patients, showed DCR of 34% (58/170). Precision cancer medicine demonstrates encouraging clinical effect in a subset of patients included in the IMPRESS-Norway trial.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile.
PATIENTS AND METHODS
METHODS
IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment. Comprehensive next-generation sequencing, TruSight Oncology 500, is used for screening. Patients with tumours harbouring molecular alterations with matched targeted therapies available in IMPRESS-Norway, are offered treatment. Currently, 24 drugs are available in the study. Primary study endpoints are percentage of patients offered treatment in the trial, and disease control rate (DCR) defined as complete or partial response or stable disease in evaluable patients at 16 weeks (W16) of treatment. Secondary endpoint presented is DCR in all treated patients.
RESULTS
RESULTS
Between April 2021 and October 2023, 1,167 patients were screened, and an actionable mutation with matching drug was identified for 358 patients. By the data cut off 186 patients have initiated treatment, 170 had a minimum follow-up time of 16 weeks, and 145 also had evaluable disease. In patients with evaluable disease, the DCR was 40% (58/145). Secondary endpoint analysis of DCR in all treated patients, showed DCR of 34% (58/170).
INTERPRETATION
CONCLUSIONS
Precision cancer medicine demonstrates encouraging clinical effect in a subset of patients included in the IMPRESS-Norway trial.
Identifiants
pubmed: 38779911
doi: 10.2340/1651-226X.2024.28322
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-384Investigateurs
Aida Johannessen
(A)
Almaz Nigatu Tesfahun
(AN)
Anja Nilsen
(A)
Anna Berit Wennerström
(AB)
Anne Jarstein Skjulsvik
(AJ)
Anne Renolen
(A)
Atle Granlund
(A)
Daniel Vodak
(D)
Diana Brodin
(D)
Eivind Hovig
(E)
Emiel Jansen
(E)
Hans Kristian Haugland
(HK)
Hans-Richard Brattbakk
(HR)
Hilde Nilsen
(H)
Hong Yan Dai
(HY)
John Christopher Noone
(JC)
Kari M Ersland
(KM)
Kate Myreng
(K)
Kristin Åberg
(K)
Laxmi Silval-Pandit
(L)
Leonardo Meza-Zepeda
(L)
Mari Jebens
(M)
Mehrdad Rakaee
(M)
Mette Myklebust
(M)
Ragnhild Margrethe Wold
(RM)
Rakel Brendsdal Forthun
(RB)
Robin Mjelle
(R)
Sigmund Sperstad
(S)
Silja Kavlie Fykse
(SK)
Susanne Lorenz
(S)
Tonje Lien
(T)
Tormod K Guren
(TK)
Vibeke Olsen
(V)
Vigdis Nygaard
(V)
Anastasia Nikitenko
(A)
Andrea Lenartova
(A)
Andreas Stensvold
(A)
Anne Hansen Ree
(AH)
Bjørn Henning Grønberg
(BH)
Bjørn Tore Gjertsen
(BT)
Eline Aas
(E)
Espen Enerly
(E)
Geir E Tjønnfjord
(GE)
Guro Aune
(G)
Hedda von der Lippe Gythfeldt
(H)
Hege Elvebakken
(H)
Jaroslav Bublevic
(J)
Jon Amund Kyte
(JA)
Karin Agnethe Semb
(KA)
Kristina Lindemann
(K)
Monica Cheng Munthe-Kaas
(MC)
Odd Terje Brustugun
(OT)
Olav Toai Duc Nguyen
(OTD)
Per Eystein Lønning
(PE)
Ragnhild A Lothe
(RA)
Tom Dønnem
(T)
Tonje Bøyum Riste
(TB)
Ulla Randen
(U)